ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
82.76
-1.04%
US Dollar vs AUD
1.51277
-0.60%
Bitcoin
62,808.91
6.24%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kura Oncology Inc (KURA)

  7. Kura Oncology Inc (KURA) News

KURA

Kura Oncology (KURA)

Kura Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KURA
DateTimeSourceHeadlineSymbolCompany
03/05/202421:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
03/05/202406:05GlobeNewswire Inc.Kura Oncology Reports First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
25/04/202421:30GlobeNewswire Inc.Kura Oncology to Report First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
22/04/202421:30GlobeNewswire Inc.Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
10/04/202421:30GlobeNewswire Inc.Kura Oncology to Participate in Stifel Targeted Oncology ForumNASDAQ:KURAKura Oncology Inc
05/04/202422:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
06/03/202423:30GlobeNewswire Inc.Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaNASDAQ:KURAKura Oncology Inc
02/03/202409:00GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
28/02/202408:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
28/02/202408:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
28/02/202408:01GlobeNewswire Inc.Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
26/02/202423:30GlobeNewswire Inc.Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
22/02/202423:30GlobeNewswire Inc.Kura Oncology to Participate in Three Upcoming Investor ConferencesNASDAQ:KURAKura Oncology Inc
20/02/202423:30GlobeNewswire Inc.Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
16/02/202408:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KURAKura Oncology Inc
15/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KURAKura Oncology Inc
15/02/202409:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
14/02/202409:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
10/02/202409:21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KURAKura Oncology Inc
02/02/202423:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
01/02/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
01/02/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
01/02/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
01/02/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
31/01/202408:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
30/01/202423:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
30/01/202423:00GlobeNewswire Inc.Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
27/01/202409:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
27/01/202408:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
25/01/202408:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:KURA

Your Recent History

CCOM
SILVER
SILVER
ASX
AMP
AMP
NYSE
NKE
Nike
ASX
XAO
Australian SE All Ordina...
ASX
ORG
Origin Energy
FX
AUDJPY
AUD vs Yen
ASX
XFL
S&P ASX 50
NASDAQ
MSFT
Microsoft
NYSE
JPM
JP Morgan Chase
NYSE
VZ
Verizon Communications
ASX
XTO
S&P ASX 100
ASX
NCM
Newcrest Mining
COIN
ETHUSD
Ethereum
ASX
FMG
Fortescue
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved